基本信息
views: 66

Bio
Awarded a GlaxoWellcome fellowship to support my Ph.D at Sorbonne University, my academic journey provided the foundation for a career dedicated to advancing drug discovery and innovation. Throughout my studies, I developed a passion for medicinal chemistry and synthetic methodologies, culminating in my research on Lankacidin C and Lankacyclinol during my postdoctoral work at Indiana University.
In my professional career, I've had the privilege of leading high-impact drug discovery programs at leading pharmaceutical companies, including Merck & Co. and Schering-Plough. Over the past 25 years, I've specialized in developing targeted therapies across diverse therapeutic areas, including Infectious Diseases, Oncology, CNS, and Cardiovascular Metabolic Disorders. I was a key team player in the development of breakthrough therapies like Victrelis (Boceprevir) and Arlansa (Narlaprevir), and led teams that contributed to the progression of numerous clinical candidates evaluated in human trials. My experience spans the utilization of small and large molecules, hetero-bifunctional degraders, and novel modalities ideas such as Degrader Antibody Conjugates (DAC), leveraging cutting-edge predictive sciences and Merck VLE metrics concept to accelerate therapeutic discovery.
As a strategic leader, I am passionate about mentoring the next generation of scientists, fostering cross-functional collaborations, and driving high-performing teams. I have been fortunate to earn multiple accolades, including the ACS Heroes of Chemistry Award and the Thomas Edison Patent Award, alongside over 50 patents and peer-reviewed publications.
Looking ahead, my goal is to continue advancing drug discovery through innovative therapies, global collaborations with multiple partners, and exploring new therapeutic modalities that address unmet medical needs. I aim to build on my tenure at top pharmaceutical companies by consulting with research organizations, facilitating chemical matter optimization as well as possible partnership / licensing opportunities of novel, transformative treatments that improve lives worldwide.
In my professional career, I've had the privilege of leading high-impact drug discovery programs at leading pharmaceutical companies, including Merck & Co. and Schering-Plough. Over the past 25 years, I've specialized in developing targeted therapies across diverse therapeutic areas, including Infectious Diseases, Oncology, CNS, and Cardiovascular Metabolic Disorders. I was a key team player in the development of breakthrough therapies like Victrelis (Boceprevir) and Arlansa (Narlaprevir), and led teams that contributed to the progression of numerous clinical candidates evaluated in human trials. My experience spans the utilization of small and large molecules, hetero-bifunctional degraders, and novel modalities ideas such as Degrader Antibody Conjugates (DAC), leveraging cutting-edge predictive sciences and Merck VLE metrics concept to accelerate therapeutic discovery.
As a strategic leader, I am passionate about mentoring the next generation of scientists, fostering cross-functional collaborations, and driving high-performing teams. I have been fortunate to earn multiple accolades, including the ACS Heroes of Chemistry Award and the Thomas Edison Patent Award, alongside over 50 patents and peer-reviewed publications.
Looking ahead, my goal is to continue advancing drug discovery through innovative therapies, global collaborations with multiple partners, and exploring new therapeutic modalities that address unmet medical needs. I aim to build on my tenure at top pharmaceutical companies by consulting with research organizations, facilitating chemical matter optimization as well as possible partnership / licensing opportunities of novel, transformative treatments that improve lives worldwide.
Research Interests
Papers共 88 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Chunhui Huang,Christian Fischer,Michelle R. Machacek,Stephane Bogen,Tesfaye Biftu,Xianhai Huang,Michael H. Reutershan,Ryan Otte,Qingmei Hong,Zhicai Wu,Yang Yu, Min Park,Lei Chen,Purakkattle Biju,Ian Knemeyer, Ping Lu,Christopher J. Kochansky,Michael Brendan Hicks,Yong Liu,Roy Helmy,Xavier Fradera,Anthony Donofrio,Josh Close,Matthew L. Maddess,Catherine White,David L. Sloman,Nunzio Sciammetta,Jun Lu,Craig Gibeau,Vladimir Simov,Hongjun Zhang,Peter Fuller,David Witter
Michael H. Reutershan,Michelle R. Machacek,Michael D. Altman,Stephane Bogen,Mingmei Cai, Carolyn Cammarano,Dapeng Chen,Matthew Christopher, John Cryan,Pierre Daublain,Xavier Fradera,Prasanthi Geda,Peter Goldenblatt,Armetta D. Hill,Raymond A. Kemper,Victoria Kutilek,Chaomin Li,Michelle Martinez,Mark McCoy,Latha Nair,Weidong Pan,Christopher F. Thompson,Giovanna Scapin,Manami Shizuka, Marianne L. Spatz,Dietrich Steinhuebel,Binyuan Sun,Matthew E. Voss,Xiao Wang, Liping Yang,Tammie C. Yeh,Isabelle Dussault,C. Gary Marshall,B. Wesley Trotter
Stephane L. Bogen,Weidong Pan,Craig R. Gibeau,Brian R. Lahue,Yao Ma,Latha G. Nair, Elise Seigel,Gerald W. Shipps, Yuan Tian,Yaolin Wang,Yinghui Lin,Ming Liu,Suxing Liu,Asra Mirza,Xiaoying Wang,Philip Lipar,Cynthia Seidel-Dugan,Daniel J. Hicklin,W. Robert Bishop,Diane Rindgen,Amin Nomeir,Winifred Prosise,Paul Reichert,Giovanna Scapin,Corey Strickland,Ronald J. Doll
Vinay Girijavallabhan,Ashok Arasappan,Frank Bennett,Kevin Chen,Qun Dang,Ying Huang,Angela Kerekes,Latha Nair,Dmitri Pissarnitski,Vishal Verma,Carmen Alvarez, Ping Chen,David Cole,Sara Esposite,Yuhua Huang,Qingmei Hong, Zhidan Liu,Weidong Pan,Haiyan Pu,Randall Rossman,Quang Truong,Bancha Vibulbhan, Jun Wang,Zhiqiang Zhao,David Olsen,Andrew Stamford,Stephane Bogen,F. George Njoroge
Load More
Author Statistics
#Papers: 88
#Citation: 2413
H-Index: 24
G-Index: 46
Sociability: 6
Diversity: 2
Activity: 3
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn